Arch Truth

Loss of Function Variants in <i>LRRK1</i> and <i>LRRK2</i> Not Linked to Parkinson Disease

Kinase inhibition or allele-specific targeting of mutant LRRK2 may still be a meaningful target for therapeutic development.